0001179110-20-011198.txt : 20201118 0001179110-20-011198.hdr.sgml : 20201118 20201118162310 ACCESSION NUMBER: 0001179110-20-011198 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haviland Kate CENTRAL INDEX KEY: 0001663022 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 201325385 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-11-16 0 0001597264 Blueprint Medicines Corp BPMC 0001663022 Haviland Kate C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Operating Officer Common Stock 2020-11-16 4 M 0 409 36.05 A 43247 D Common Stock 2020-11-16 4 S 0 409 100.27 D 42838 D Stock Option (Right to Buy) 36.05 2020-11-16 4 M 0 409 0 D 2027-02-16 Common Stock 409 4591 D Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100 to $100.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-11-18